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Anthrax is an infection caused by pathogenic strains of 
 
Bacillus anthracis
 
, which secretes a 
three-component toxic complex consisting of protective antigen (PA), edema factor (EF), 
and lethal factor (LF). PA forms binary complexes with either LF or EF and mediates their 
entry into host cells. Although the initial phases of bacterial growth occur in the lymph 
node, the host fails to mount an effective immune response. Here, we show that LT and ET 
are potent suppressors of human T cell activation and proliferation triggered through the 
antigen receptor. Both LT and ET inhibit the mitogen-activated protein and stress kinase 
pathways, and both toxins inhibit activation of NFAT and AP-1, two transcription factors 
essential for cytokine gene expression. These data identify a novel strategy of immune 
evasion by 
 
B. anthracis
 
, based on both effector subunits of the toxic complex, and targeted 
to a key cellular component of adaptive immunity.
 
Anthrax is an infection caused by pathogenic
strains of 
 
Bacillus anthracis
 
. After entering the
body though skin abrasions, ingestion, or inha-
lation, 
 
B. anthracis
 
 spores are phagocytosed by
macrophages that migrate to regional lymph
nodes. There, the spores germinate and become
vegetative bacteria that lyse the macrophage,
multiply in the lymphatic system, and enter the
bloodstream, causing septicemia and toxemia
and eventually leading to death of the host (1).
 
B. anthracis
 
 secretes a binary A-B toxin com-
posed of a single B protomer, protective antigen
(PA), and two alternative A proteins, lethal
factor (LF) and edema factor (EF). PA interacts
with different cell surface receptors and, after
proteolytic activation, self-associates to form
membrane-inserting heptamers that bind LF
and EF (2–4). PA 
 
  
 
LF (lethal toxin [LT]) and
PA 
 
  
 
EF (edema toxin [ET]) complexes enter
surface rafts (5) and are internalized into acidic
endosomal compartments. Low pH triggers a
conformational change that results in LF and
EF translocation into the cytosol of the host
cell (2–4). LF is a zinc metalloprotease that
cleaves mitogen-activated protein kinase kinases
(MAPKK; references 6–8), thereby interfering
with the MAPK cascade, a crucial component
in signaling by surface receptors controlling
cell proliferation and survival. EF is a calcium/
calmodulin-dependent adenylylcyclase that cat-
alyzes massive production of cAMP, with
ensuing alteration of intracellular signaling
pathways (9).
Although manifestations of advanced disease
are believed to be caused by anthrax toxin,
host–pathogen interactions occurring in the
lymph node are as yet largely elusive. LT
blunts the release of proinflammatory mediators
by macrophages and dendritic cells and pro-
motes their apoptosis, thereby preventing phago-
cyte  recruitment and bacterial clearance (10,
11). Furthermore, LT impairs dendritic cell
function and interferes with initiation of adap-
tive immune responses (12). To date, the out-
come of 
 
B. anthracis
 
 infection on T lymphocytes,
the central regulators of adaptive immunity, has
not been addressed, although these cells can
be exposed to the toxin in the lymph node,
and several steps in the signaling cascade ini-
tiated by the TCR may be potentially dis-
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Figure 1. Anthrax toxins suppress T cell activation.
 
 Flow cytometric 
analysis of CD69 (A) or CD25 (B) expression on PBLs activated for 16–24 h 
by CD3 cross-linking in the presence or absence of 200 ng/ml PA and the 
indicated concentrations of either LF or EF. (C) CD69 expression on PBLs ac- 
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rupted by the activities of LF and EF (13–15). Here, we have
investigated the outcome of T lymphocyte exposure to an-
thrax toxins.
 
RESULTS AND DISCUSSION
 
Commitment to T cell activation is characterized by the
temporally regulated expression of genes encoding proteins
that include transcription factors, cell surface receptors, and
cytokines. The end of the commitment phase is marked by
expression of IL-2 and IL-2R, which initiate an autocrine
proliferation loop resulting in clonal expansion of antigen-
specific T cells (16). To determine the effect of LT or ET on
T cell activation, human PBLs were treated for 6 h with PA
or PA in combination with varying amounts of LF or EF.
After washing, cells were stimulated by TCR/CD3 ligation
for 16–24 h. Trypan blue exclusion showed that neither
toxin affected cell viability to a significant extent, even at the
highest concentration used (not depicted). Surface expres-
sion of CD69, an early activation marker, and of CD25, the
high affinity subunit of the IL-2 receptor, was measured by
flow cytometry. Both LT and ET inhibited the expression of
both CD69 (Fig. 1 A) and CD25 (Fig. 1 B) in a dose-
responsive fashion. No effect was observed when cells were
treated with PA, LF, or EF alone (not depicted). The speci-
ficity of these activities was confirmed by using selective in-
hibitors of LF and EF. Epigallocatechin-3-gallate (EGCG), a
specific LF inhibitor (17), and adefovir dipivoxil, a specific
EF inhibitor (18), selectively reversed the effect of LF and
EF, respectively (Fig. 1 C and not depicted). Remarkably,
when LT and ET were used together at the lowest concen-
tration, which alone affected only weakly CD69 expression,
a significant inhibition was observed, indicating a synergism
of the two toxins (Fig. 1 D). The effect of anthrax toxins on
cytokine production was assessed by quantitating the levels
of IFN-
 
 
 
, IL-2, IL-5, and TNF
 
 
 
 in the culture supernatants
of cells treated as described before and incubated for 30 h. As
shown in Fig. 1 E, both LF and EF profoundly inhibited cy-
tokine expression, further underlining the suppressive effect
of anthrax toxins on T cell activation.
Long-term effects of the anthrax toxins on T cell prolifer-
ation were assayed by flow cytometric analysis of PBLs
treated with LT or ET for 6 h and loaded, after washing, with
the fluorescent vital dye, CFSE, which binds irreversibly to
cellular proteins, followed by activation by TCR/CD3 cross-
linking. TCR-dependent T cell proliferation was first detect-
able 48 h after activation (not depicted) and, by 72 h, a signif-
icant proportion of T lymphocytes was dividing, with up to
three rounds of division. LT, and to an even larger extent
ET, markedly inhibited cell proliferation (Fig. 2).
LF cleaves MAPKKs, including MEK1/2 and MKK3/4/
6/7 (6–8), which are the intermediate members of the MAP
and stress kinase cascades initiated by the small GTPases Ras
and Rho/Rac/cdc42, respectively (19). Cleavage occurs within
the NH
 
2
 
-terminal proline-rich region preceding the kinase
domain, thus disrupting a sequence involved in the protein–
protein interactions required for activation of their down-
stream MAPK targets (20, 21). The effect of LT on the in-
 
tivated for 16 h by CD3 cross-linking in the presence or absence of 200 ng/
ml PA and 10 ng/ml LF or EF, in combination with 10 
 
 
 
M EGCG or 5 
 
 
 
M 
adefovir dipivoxil. EGCG or adefovir dipivoxil alone did not affect CD69/
CD25 expression either on quiescent or activated cells (not depicted). The 
inhibitory effect of LF on CD69/CD25 expression was not affected by adefovir 
dipivoxil, nor the effect of EF by EGCG (not depicted). (D) CD69 expression 
on PBLs activated for 16 h by CD3 cross-linking in the presence or absence 
of 200 ng/ml PA and 10 ng/ml LF or 10 pg/ml EF, either alone or in combi-
nation. Representative experiments are shown (
 
n 
 
  
 
3). (E) Quantitation of 
cytokines (pg/ml) in the supernatants of PBLs activated for 30 h by CD3 
cross-linking in the presence or absence of 200 ng/ml PA and the indicated 
concentrations of LF or EF (
 
 
 
g/ml) (
 
n 
 
  
 
2). Error bars, SD.
Figure 2. Suppression of T cell proliferation by anthrax toxins. Flow 
cytometric analysis of CFSE-labeled PBLs stimulated for 72 and 96 h by 
CD3 cross-linking ( -CD3) in the presence or absence of 200 ng/ml PA 
and 10 ng/ml (LF10, EF10) or 1 ng/ml (LF1, EF1) LF or EF. CFSE fluorescence 
was analyzed on gated CD3  cells. CFSE staining in unstimulated CD3  
cells is shown as an unshaded histogram. The percentage of CD3  cells 
having undergone proliferation is indicated. Data from a representative 
experiment are shown (n   3). For each experiment, proliferation was 
monitored at 24, 48, 72, 96, 120, and 148 h. 
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Figure 3. Anthrax toxins disrupt MAP and stress kinase activation.
 
 
Immunoblot analysis of postnuclear supernatants from PBLs activated for 
5 min by CD3 cross-linking (
 
 
 
-CD3) in the presence or absence of 0.2–2 
 
 
 
g/ml 
PA and 1–10 
 
 
 
g/ml LF or EF, in combination with 10 
 
 
 
M EGCG or 5 
 
 
 
M  
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tegrity and activation of MEK1/2 was assessed. PBLs were
treated for 6 h with either LT or ET, washed, and activated by
TCR/CD3 cross-linking for 5 min. Cells were lysed, and
postnuclear supernatants were subjected to immunoblot analy-
sis using anti-MEK1/2 antibodies. Fig. 3 A shows that PBL
treatment with LT resulted in the conversion of MEK1/2 to a
higher electrophoretic mobility form consistent with removal
of a NH
 
2
 
-terminal, 
 
 
 
800 Da fragment. ET had no effect, and
the shift in apparent MW was inhibited by EGCG, which
blocks the proteolytic cleavage of MEKs by LF (17), but not
by adefovir dipivoxil (Fig. 3 A and not depicted). In agree-
ment with these results, immunoblot analysis of the stripped
filters with an antibody that specifically recognizes the NH
 
2
 
terminus of MEK2 showed that the MEK2-specific immu-
noreactivity was significantly reduced in LT-treated PBLs, but
not in PBLs treated with LT in the presence of EGCG, nor in
ET-treated PBLs (not depicted). Probing the same lysates with
antibodies against phosphorylated, active MEK1/2 showed
that MEK1/2 phosphorylation was not impaired by LT (Fig.
3, A and G), consistent with the fact that MAPKK cleavage
does not affect the site of interaction with Raf, its upstream ki-
nase, nor its phosphorylation sites (22). Furthermore, Ras acti-
vation was not affected, as shown by pulldown assays using a
GST-Raf fusion, which interacts with GTP-bound, active
Ras (Fig. 3 B). Alternatively, activation of Erk, the MAPK
downstream of MEK, was profoundly inhibited by LT. This
effect was selectively reversed by EGCG, but not by adefovir
dipivoxil (Fig. 3, C and G, and not depicted). Furthermore, in
agreement with the capacity of LF to cleave a wide panel of
MAPKKs (8), activation of the stress-kinases JNK and p38,
which is mediated by MKK4/7 and MKK3/6, respectively
(19), was also blocked by LT (Fig. 3, D, E, and G).
Interestingly, although ET did not affect the integrity of
MEK1/2, it significantly reduced its activation (Fig. 3, A and
G), as well as Erk activation (Fig. 3, C and G). PBL treat-
ment with ET resulted in increased intracellular cAMP,
which was blocked by adefovir dipivoxil (Fig. 3 F). The
PKA-dependent inhibitory effect of cAMP on the activation
of Raf (23), the serine-threonine kinase upstream of MEK, is
likely to underlie the inhibition of MEK activation by ET.
MEK/Erk inhibition by ET was reversed by adefovir dipiv-
oxil but not by EGCG (Fig. 3, A, C, and G, and not de-
picted). These results highlight MEK as a point of conver-
gence of the immunosuppressive activities of LT and ET. Of
note, TCR-dependent JNK activation (Fig. 3, D and G),
but not p38 activation (Fig. 3, E and G), was also impaired
 
adefovir dipivoxil. Immunoblots were performed with antibodies against 
the phosphorylated, active forms of MEK (A), Erk (C), JNK (D), or p38 (E). 
Filters were stripped and reprobed with anti-MEK (A), Erk (C), tubulin (D), or 
p38 (E) antibodies. Arrows indicate the full-length and cleaved forms of 
MEK (A). The inhibitory effects of LF were not affected by adefovir dipivoxil, 
nor the effect of EF by EGCG (not depicted). Neither EGCG nor adefovir 
dipivoxil had any effect on MAP or stress kinase activity in untreated, non-
stimulated or anti-CD3–stimulated cells (not depicted). Representative ex-
periments are shown (
 
n 
 
  
 
3). (B, left) Immunoblot analysis using anti-Ras 
mAb of in vitro binding assays to agarose-bound GST-Raf of postnuclear 
supernatants from PBLs activated as described before in the presence or 
absence of 200 ng/ml PA and 10 
 
 
 
g/ml LF. Total cell lysates separated on 
the same gel are shown (right). (F) Quantitation of cAMP in lysates of PBLs 
treated with 2 
 
 
 
g/ml PA and 1 
 
 
 
g/ml EF, in the presence or absence of 5 
 
 
 
M 
adefovir dipivoxil. Error bars, SD. (G) Densitometric analysis of data from 
multiple experiments on the effects of LT and ET on Erk, JNK, p38, and MEK 
phosphorylation, in the absence or presence of EGCG or adefovir dipivoxil. 
The results are shown as the percentage of the phosphorylation levels of 
each kinase in anti-CD3–stimulated PBLs (100%) after normalization to 
the respective controls.
Figure 4. Inhibition of TCR-dependent NFAT and AP-1 activation by 
anthrax toxins. (A) Relative luciferase activity in NF-AT/luciferase reporter 
Jurkat cells (left) or Jurkat cells transiently transfected with an AP-1/luciferase 
reporter (right), activated by CD3 cross-linking in the presence or absence 
of 200 ng/ml PA and the indicated concentrations of LF or EF and, where 
indicated, 10  M EGCG. The data are expressed as percentage of luciferase 
activity induced by CD3 cross-linking (100%) (n   3 for NFAT, n   3 for 
AP-1). Error bars, SD. (B) Confocal microscopy of Jurkat cells transiently 
transfected with a NFAT/GFP expression construct, either unstimulated (0) 
or activated by CD3 cross-linking for 30 min, in the absence or presence of 
200 ng/ml PA and 1  g/ml LF or EF. Percentage of cells showing nuclear 
staining in a representative experiment were as follows: no activation, 0%; 
CD3XL, 72.5%; LT, 9.4%; ET, 4.0%; CD3XL   LT, 68.0%; CD3XL   ET, 71.9% 
(no. of GFP  cells scored  50). 
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in cells treated with ET, suggesting a selectivity in the inhib-
itory activity of ET for specific MAP/stress-kinase cascades.
MAP kinases link triggering of surface receptors to gene
transcription (13, 19). The transcription factor NFAT plays a
crucial role in the transcriptional regulation of several cyto-
kine-encoding genes, including the genes for IL-2 and IL-2R
(24). NFAT is composed of a nuclear subunit, AP-1, which
is activated by MAPKs, and a cytosolic subunit, which trans-
locates into the nucleus to assemble with AP-1 after dephos-
phorylation by the phosphatase calcineurin. The latter is ac-
tivated by the elevation in intracellular [Ca
 
2
 
 
 
]
 
i
 
 triggered by
TCR engagement (24). The effect of anthrax toxins on
TCR-dependent NFAT activation was determined using a
reporter Jurkat T cell line stably transfected with a construct
encoding luciferase under the control of a trimer of the
NFAT binding site on the IL-2 gene promoter. Consistent
with the requirement for MAP and stress kinases in NFAT
activation (24, 25), LT inhibited NFAT–driven luciferase
expression in a dose-dependent fashion, and this effect was
prevented by EGCG (Fig. 4 A). Inhibition of NFAT activa-
tion by LT resulted, at least in part, from AP-1 inhibition by
the toxin, as shown in transient transfection experiments us-
ing an AP1/luciferase reporter (Fig. 4 A). However, LT did
not affect the Ca
 
2
 
 
 
–calcineurin pathway. Indeed, LT had no
effect on TCR-dependent NFAT translocation to the nu-
cleus, as determined by confocal microscopy of Jurkat cells
transiently transfected with a NFAT–GFP fusion (Fig. 4 B).
Furthermore, LT did not affect [Ca
 
2
 
 
 
]
 
i
 
 flux triggered by
TCR/CD3 ligation in PBLs (not depicted).
TCR-dependent NFAT activation was also inhibited by
ET, albeit only at the highest dose used (Fig. 4 A). This ef-
fect appears dependent on the capacity of ET to block Erk
and JNK, which control AP-1 activation (19), as AP-1–
driven luciferase expression was also inhibited by ET (Fig. 4
A), whereas NFAT/GFP nuclear translocation was not af-
fected by the toxin (Fig. 4 B). Of note, a combination of PA
with 10 ng/ml EF and 10 pg/ml LF, which alone did not af-
fect NFAT–driven luciferase expression, resulted in signifi-
cant inhibition of NFAT activation (Fig. 4 A), indicating a
synergism of the two toxins. Interestingly, as opposed to
NFAT, AP-1 activation was inhibited also at lower ET con-
centrations (Fig. 4 B). The lack of effect of ET on the activa-
tion of p38, which is implicated in the control of NFAT, but
not AP-1 activity (25), is likely to underlie the different sen-
sitivity of the two transcription factors to ET.
The present results identify T lymphocytes as a novel
cellular target of anthrax toxins and show that the intracellu-
lar activities of both LT and ET converge in these cells on
the signaling cascade initiated by the TCR, resulting in sup-
pression of cell activation and proliferation. Although the
causal role of the anthrax toxic complex in the advanced
phase of infection has been largely elucidated, the failure of
the host to mount an effective immune response is as yet
elusive. Adaptive immunity is initiated in the lymph node,
where vegetative bacteria are released from infected mac-
rophages and can be taken up by dendritic cells, processed,
and presented to T cells. LT has been shown recently to in-
terfere with MAPK signaling in dendritic cells, thereby sup-
pressing their maturation and capacity to prime adaptive re-
sponses (12). The data reported here highlight T lymphocytes
as direct cellular targets of both LT and ET. The two toxins
cooperatively inhibit T cell activation at very low concentra-
tions, similar to those expected in the early stages of infec-
tion. By suppressing the activation of both dendritic cells and
T cells, which together are responsible for initiating adaptive
immune responses, 
 
B. anthracis
 
 has evolved a highly effective
strategy of immune evasion.
 
MATERIALS AND METHODS
 
Cells, reagents, and antibodies.
 
Cells included the T lymphoma Jurkat
line and a stably transfected Jurkat line expressing luciferase under the control
of a trimer of the distal NFAT binding site on the IL-2 promoter (26). PBLs
were purified from the whole blood of healthy donors by density gradient
centrifugation and subsequent depletion of monocytes by adherence. Phos-
pho-specific antibodies recognizing the active forms of MEK1/2, Erk1/2,
JNK, and p38, and anti-MEK1/2 antibodies were obtained from Cell Sig-
naling Technology; anti-p38 and anti-Erk antibodies, as well as an anti-
MEK2 antibody specific for its NH
 
2
 
 terminus, were obtained from Santa
Cruz Biotechnology, Inc.; antitubulin mAb was obtained from Amersham
Biosciences. Fluorochrome-labeled anti-CD3, anti-CD69, and anti-CD25
mAb were obtained from Becton Dickinson. IgG from OKT3 (anti-CD3;
American Type Culture Collection) hybridoma supernatants were protein G
purified. Unlabeled secondary antibodies were from Cappel and peroxidase-
labeled antibodies were obtained from Amersham Biosciences. Sepharose-
conjugated GST-Raf and anti-Ras mAb were from Upstate Biotechnology.
PA and LF were expressed and purified as described previously (27). The EF
gene from the plasmid pMMA187 (28) was PCR amplified using the follow-
ing primers: 5
 
 
 
-AAAGGATCCTCCATGAATGAACATTACACTGAG-
3
 
 
 
 (forward) and 5
 
 
 
-AAAGAGCTCTTATTTTTCATCCATAATTTT-
TTGG-3
 
 
 
 (reverse). The PCR fragment obtained was digested with BamHI
and SacI and inserted in pRSET A (Invitrogen). The cloned sequence was
confirmed by DNA sequencing. The protein was expressed as NH
 
2
 
-terminal
His-tag fusion in BL21 DE3 (Novagen Inc.) and purified by Ni-charged
Hitrap chelating (Amersham Biosciences). EGCG was purchased from Sigma-
Aldrich and adefovir dipivoxil was synthesized and supplied by Gilead Sci-
ences Inc. Cells were plated at 5 
 
 
 
 10
 
6
 
 cells/ml in RPMI 1640 supple-
mented with 7.5% FCS complete medium, added with LT and/or ET, and
incubated at 37
 
 
 
C for 6 h. EGCG was preincubated with LT or ET for 15
min at 37
 
 
 
C before addition to the cells. Cells were preincubated with ade-
fovir dipivoxil at 37
 
 
 
C for 2–6 h before addition of LT or ET.
 
Activations, in vitro binding assays, immunoblots, luciferase as-
says, and cytokine and cAMP measurements.
 
For immunoblot and in
vitro binding experiments, activations by TCR/CD3 ligation were per-
formed by incubating cells with anti-CD3 mAb and secondary antibodies
for 5 min at 37
 
 
 
C as described previously (29). For analysis of CD69/CD25
and luciferase expression, cells were activated by CD3 cross-linking on sec-
ondary antibody-coated plates (29) and processed for flow cytometry 16–24 h
after activation. NFAT/luciferase reporter Jurkat cells were collected 16 h
after activation and processed for luciferase assays (29). In vitro binding as-
says and immunoblots were performed as described previously (30) and
quantitated by laser densitometry (Kodak Digital Science Electrophoresis
Documentation and Analysis System 120). Intracellular cAMP was quanti-
tated by enzyme-linked immunoassay (Biotrak EIA; Amersham Bio-
sciences). Cytokines were measured using the Human Cytokine ELISA kit
obtained from Bender MedSystems.
 
Transfections, confocal microscopy, and flow cytometry.
 
Jurkat
cells were transiently transfected with the plasmid pEGFP/NFAT-1D (31) 
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or an AP-1/luciferase reporter using a modification of the DEAE/dextran
procedure as described previously (29). Confocal microscopy was per-
formed on a confocal microscope (Microsystems; Leica). CD3, CD69, and
CD25 surface expression was quantitated by flow cytometry using fluoro-
chrome-labeled mAb. Samples were processed using a FACScan flow cy-
tometer (Becton Dickinson). T cell proliferation was measured by flow cy-
tometric analysis of CFSE-labeled cells, counterstained with anti-CD3 mAb
as described previously (30). Cells were analyzed 24–172 h after stimulation.
Intracellular flux of calcium ions was measured as described previously (29)
using FF-fluo-4 (Molecular Probes).
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